Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma
Stopped early · Phase 1
Conditions studied: Brain and Central Nervous System Tumors
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy placed into the surrounding tissue after surgery to remove the tumor may kill any remaining tumor cells. O(6)-benzylguanine may increase the effectiveness of carmustine by making tumor cells more sensitive to the drug. PURPOSE: Phase I trial to study the safety of combining O(6)-benzylguanine with carmustine implants in treating children who have recurrent malignant glioma.
Key facts
- Study ID
- NCT00045721
- Run by
- Pediatric Brain Tumor Consortium
- People needed
- 3
- Starts
- 2003-03-01
- Expected to finish
- 2004-07-01
- Last updated by the study team
- 2009-10-16
Who can join
Age: 3 and older, up to 21. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCSF Comprehensive Cancer Center — San Francisco, California, United States
- Children's National Medical Center — Washington D.C., District of Columbia, United States
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Duke Comprehensive Cancer Center — Durham, North Carolina, United States
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
- Children's Hospital of Pittsburgh — Pittsburgh, Pennsylvania, United States
- St. Jude Children's Research Hospital — Memphis, Tennessee, United States
- Texas Children's Cancer Center — Houston, Texas, United States
- Children's Hospital and Regional Medical Center - Seattle — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.